A phase II study with CD20-positive non-Hodgkin's lymphoma treated with shorter duration of infusion of GA101(RO5072759)

Trial Profile

A phase II study with CD20-positive non-Hodgkin's lymphoma treated with shorter duration of infusion of GA101(RO5072759)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms GATS trial
  • Sponsors Chugai Pharmaceutical; Nippon Shinyaku
  • Most Recent Events

    • 06 Dec 2016 Results assessing safety and pharmacokinetics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Nov 2016 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
    • 27 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top